112 related articles for article (PubMed ID: 37327705)
1. Targeted co-delivery of PD-L1 monoclonal antibody and sorafenib to circulating tumor cells via platelet-functionalized nanocarriers.
Da X; Mo J; Li Q; Cao B; Huang J; Lu Y; Lu L; Fan M; Lu H
Biochem Biophys Res Commun; 2023 Sep; 671():335-342. PubMed ID: 37327705
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets.
Da X; Cao B; Mo J; Xiang Y; Hu H; Qiu C; Zhang C; Lv B; Zhang H; He C; Yang Y
BMC Cancer; 2024 Feb; 24(1):273. PubMed ID: 38409035
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer.
Darga EP; Dolce EM; Fang F; Kidwell KM; Gersch CL; Kregel S; Thomas DG; Gill A; Brown ME; Gross S; Connelly M; Holinstat M; Cobain EF; Rae JM; Hayes DF; Paoletti C
PLoS One; 2021; 16(11):e0260124. PubMed ID: 34780566
[TBL] [Abstract][Full Text] [Related]
4. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
5. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of post-surgery tumour recurrence via a sprayable chemo-immunotherapy gel releasing PD-L1 antibody and platelet-derived small EVs.
Zhao J; Ye H; Lu Q; Wang K; Chen X; Song J; Wang H; Lu Y; Cheng M; He Z; Zhai Y; Zhang H; Sun J
J Nanobiotechnology; 2022 Feb; 20(1):62. PubMed ID: 35109878
[TBL] [Abstract][Full Text] [Related]
7. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P
Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175
[TBL] [Abstract][Full Text] [Related]
8. Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.
Tan Z; Yue C; Ji S; Zhao C; Jia R; Zhang Y; Liu R; Li D; Yu Q; Li P; Hu Z; Yang Y; Xu J
Oncologist; 2021 Dec; 26(12):e2227-e2238. PubMed ID: 34516729
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells.
Xu S; Cui F; Huang D; Zhang D; Zhu A; Sun X; Cao Y; Ding S; Wang Y; Gao E; Zhang F
Int J Nanomedicine; 2019; 14():17-32. PubMed ID: 30587982
[TBL] [Abstract][Full Text] [Related]
10. Platelets as platforms for inhibition of tumor recurrence post-physical therapy by delivery of anti-PD-L1 checkpoint antibody.
Han X; Chen J; Chu J; Liang C; Ma Q; Fan Q; Liu Z; Wang C
J Control Release; 2019 Jun; 304():233-241. PubMed ID: 31071371
[TBL] [Abstract][Full Text] [Related]
11. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P
Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135
[TBL] [Abstract][Full Text] [Related]
12. Size-optimized nuclear-targeting phototherapy enhances the type I interferon response for "cold" tumor immunotherapy.
Zhang X; Yi C; Zhang L; Zhu X; He Y; Lu H; Li Y; Tang Y; Zhao W; Chen G; Wang C; Huang S; Ouyang G; Yu D
Acta Biomater; 2023 Mar; 159():338-352. PubMed ID: 36669551
[TBL] [Abstract][Full Text] [Related]
13. Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy.
Ke Y; Xiang C
Int J Nanomedicine; 2018; 13():8339-8354. PubMed ID: 30584304
[TBL] [Abstract][Full Text] [Related]
14. Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells.
Lian S; Xie R; Ye Y; Lu Y; Cheng Y; Xie X; Li S; Jia L
Sci Rep; 2019 Mar; 9(1):4532. PubMed ID: 30872703
[TBL] [Abstract][Full Text] [Related]
15. Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma.
Chen Y; Luo X; Liu Y; Zou Y; Yang S; Liu C; Zhao Y
Int J Nanomedicine; 2022; 17():3989-4008. PubMed ID: 36105615
[TBL] [Abstract][Full Text] [Related]
16. Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles.
Li J; Ai Y; Wang L; Bu P; Sharkey CC; Wu Q; Wun B; Roy S; Shen X; King MR
Biomaterials; 2016 Jan; 76():52-65. PubMed ID: 26519648
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer.
Zhou Q; Liu X; Li J; Tong B; Xu Y; Chen M; Liu X; Gao X; Shi Y; Zhao J; Zhong W; Wang M
Thorac Cancer; 2023 Feb; 14(5):470-478. PubMed ID: 36630992
[TBL] [Abstract][Full Text] [Related]
18. Platelet-mimicking nanoparticles co-loaded with W
Zuo H; Tao J; Shi H; He J; Zhou Z; Zhang C
Acta Biomater; 2018 Oct; 80():296-307. PubMed ID: 30223092
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma.
Wang Y; Li H; Liang Q; Liu B; Mei X; Ma Y
Tumour Biol; 2015 Mar; 36(3):1561-6. PubMed ID: 25371070
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma.
Zhao B; Dong Z; Liu W; Lou F; Wang Q; Hong H; Wang Y
J Nanobiotechnology; 2021 May; 19(1):124. PubMed ID: 33933077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
